XRAY (Dentsply Sirona) Stock Outlook 2026: Recurring Consumables vs a Stubborn Turnaround

Start With Why XRAY Is Cheap, Not Whether It’s Cheap

The first question to ask about Dentsply Sirona is not “is it undervalued” but “why has it stayed undervalued for so long.” The world’s largest dental products company, consumables the profession can’t skip, a CEREC base installed in practices across the globe. On asset quality alone this looks like a business that should command a premium. The stock has not behaved that way.

Here is my read, stated plainly. XRAY sits on genuinely good business assets, and it trades at a trust discount the market attached because of a long history of poor execution on top of those assets. The recurring consumables floor is real. What sits above it, the volatility of the equipment cycle and a string of self-inflicted wounds since the 2016 merger, is what keeps the multiple depressed. The investment decision is not “are the assets good.” It is “does this management team finish the job this time.”

That distinction matters. Buy Dentsply Sirona as a plain “defensive play on dentistry” and you will be caught off guard when the equipment segment lurches with the discretionary cycle. Classify it correctly as an execution-dependent turnaround and you immediately know what to check each quarter, and you have a reason to be patient.

If you have ever had a crown fitted, a root canal done, or a routine cleaning, you probably never registered whose products were in play at each step. Dentsply Sirona quietly supplies a large slice of that invisible chain. Both the appeal and the trap of this stock start right there.

👉 For a cleaner version of the same recurring-consumables model in a “picks and shovels” health business, compare with the TMO Thermo Fisher stock outlook.

---

The Floor: Why Consumables Revenue Doesn’t Collapse

The backbone of the XRAY thesis is the consumables segment: implants, prosthetic materials, endodontic files and fillings, preventive and hygiene products, and orthodontic supplies. These are the items a dental practice burns through case after case.

Break the defensiveness into layers.

Demand gets delayed, not deleted. Decay, periodontal disease, and fractured teeth don’t heal themselves. When money is tight, patients postpone elective, high-ticket work like implants, but painful, necessary procedures such as root canals and fillings continue. There is a spectrum of necessity inside consumables, and the necessary end holds the floor.

Installed habits create switching costs. A dentist who has mastered a particular implant system or file geometry doesn’t casually switch. Clinical protocols, prosthetic component compatibility, and staff proficiency are all tied to a specific brand. That “muscle memory” drives repeat purchasing.

Aging demographics compound maintenance demand. The more people walking around with implants, the larger the long-run stream of maintenance, repair, and revision consumables. That is a demographic tailwind, not a single year’s economy.

The catch is that this good floor is not the whole company. The equipment segment sits on top of it, and that is where the story gets complicated.

---

Equipment and CAD/CAM: The CEREC Base Is Both Asset and Cyclical Exposure

The second engine is Technologies and Equipment, and its flagship is CEREC, a chairside CAD/CAM system that scans, designs, and mills a crown, inlay, or onlay in a single visit. Around it sit intraoral scanners, panoramic and CBCT imaging, and treatment units.

CEREC’s appeal is that it is itself a razor-and-blade machine. Sell the mill once, and every crown milled consumes a ceramic block, with software upgrades and service contracts following. The global CEREC installed base is a quiet annuity.

Category	Nature	Revenue profile	Cycle sensitivity
Equipment sale (CEREC, scanner, imaging)	One-time capital good	Large, lumpy	High (discretionary capex)
Blocks and milling consumables	Recurring supply	Small, regular	Low
Software and service	Subscription, contract	Recurring, predictable	Low
Implant and prosthetic materials	Recurring supply	High necessity	Medium

Here is the core tension. The equipment sale itself is heavily exposed to the discretionary cycle. A practice owner facing economic uncertainty or high rates defers a five-figure equipment upgrade. Meanwhile the consumable and software revenue that equipment throws off stays steady.

So Dentsply Sirona’s quarters often wear two faces. Weak equipment sales at a cycle trough drag the headline growth rate down, while underneath, the recurring revenue holds. An investor who reads only the headline and walks away misses how solid the floor actually is.

---

What Kept Going Wrong After the 2016 Merger

You can’t understand XRAY without the 2016 merger. Consumables leader Dentsply and equipment leader Sirona combined to pitch themselves as dentistry’s one-stop supplier. The logic was sound: pair the stability of consumables with the growth of equipment under one roof.

Execution was the problem. Distributor inventory resets, integration delays, repeated goodwill impairments, management turnover, and an internal accounting probe with related litigation all followed. The market stamped “good assets, bad execution” on the company, and that trust discount showed up in the valuation.

The turnaround thesis is, at its core, about removing that discount. If new leadership tidies the cost structure, simplifies the brand portfolio, concentrates resources on the growth segments (implants and aligners), and restores predictability to free cash flow and capital allocation, the market narrows the discount. If execution slips again, the discount persists or widens.

My judgment: “it’s cheap” is not the thesis. It’s cheap for a reason, and you need quarterly evidence that the reason (execution) is improving. Screen for low P/E and low P/B and buy blindly, and this is a textbook value-trap candidate.

---

Clear Aligners: Only Option Value in Align’s Shadow

Dentsply Sirona is in clear aligners too. SureSmile targets the doctor channel, Byte targeted the direct-to-consumer channel. But be honest about who owns this market: Align Technology’s Invisalign. The gap in brand recognition, accumulated clinical data, and dentist training networks is wide.

Byte’s DTC model proved especially rough. Straightening teeth without a dentist’s in-person supervision could not stay clear of regulatory and safety controversy, and the company at one point pulled the product from sale. That episode exposed the fragility of the DTC model broadly, the same current that swept SmileDirectClub into bankruptcy.

So I treat aligners as an option, not the core thesis. Success is a growth bonus; failure still leaves the consumables floor holding the company up. Rather than reacting to every quarter’s aligner result, an investor is better served remembering it is a small slice of the whole picture.

That is the decisive difference from ALGN. For Align, Invisalign is everything. For Dentsply Sirona, aligners are one of several growth options.

👉 For another face of defensive healthcare where necessity and regulation carry the revenue, see the ELV Elevance Health stock outlook.

---

Competitive Terrain: Broad Generalist vs Focused Specialists

Dentsply Sirona’s edge is breadth. A portfolio that supplies consumables, equipment, imaging, and aligners in one relationship is convenient for dealers and practice owners. But in every sub-category, a specialist that concentrates on that niche is waiting.

Competitive arena	Key rivals	Nature of threat
Implants	Straumann, Envista (Nobel Biocare)	Pressure in the premium, growth segment
Clear aligners	Align Technology (Invisalign)	Overwhelming scale and brand gap
Scanners and CAD/CAM	Align (iTero), 3Shape, Envista	Digital-workflow competition
Consumables, endo, preventive	Envista, many global brands	Price and distribution competition

The generalist’s dilemma lives here. A wide portfolio is good for defense, but it is hard to set the pace of innovation in every field, because a specialist can pour its R&D into a single category. Whether Dentsply Sirona can match Straumann and Envista’s growth momentum in implants, and whether it can hold its own against the Align and 3Shape digital ecosystems in scanning and CAD/CAM, is the real measure of long-term competitiveness.

Even so, breadth itself is an asset that’s hard to replicate. A global distribution network, relationships with dental schools and hospitals worldwide, and a vast installed base can’t be matched overnight by a new entrant.

👉 The way a diversified industrial runs many specialized units under one owner is worth comparing with the decentralized model in the ITW Illinois Tool Works stock outlook.

---

Three Practical Scenarios for a US-Based Investor

Scenario 1: Positioning It as a Recovery Bet

If XRAY goes into a portfolio, it belongs in the value-and-recovery bucket, not the growth sleeve. A stock with good asset quality and a compressed valuation offers double leverage when execution improves: earnings recover and the multiple re-rates together. The reverse is equally true. Slip again, and an earnings miss meets further multiple compression.

A sensible sizing frame: cap the single-name weight near 5% and add as the evidence of execution (margin recovery, stable consumables, debt reduction) accumulates. Starting at a large weight and then being asked to endure is the structure to avoid.

For US taxable accounts, remember the holding-period line: a position sold after more than a year qualifies for long-term capital gains rates rather than higher short-term rates, which suits a turnaround you plan to hold patiently anyway.

👉 For a wider view on blending growth and recovery names by sector, use the AI stocks investment guide 2026.

Scenario 2: Managing Tax Lots on a Multi-Year Hold

Turnarounds arrive late, so holding periods stretch out, which makes tax-lot management worth planning. In a taxable brokerage account, you can harvest losses in a down year to offset other gains, and let winners ride past the one-year mark for long-term treatment. If the recovery finally lands and the position runs, staggering sales across tax years can smooth the bill rather than realizing everything in one high-income year.

Just as important, decide in advance whether XRAY lives in a taxable account or a tax-advantaged one (IRA/Roth). A slow-compounding recovery name with a dividend can be a reasonable fit for a tax-sheltered sleeve, where the reinvested dividend compounds without an annual drag.

👉 The mechanics of realizing and reporting gains are laid out in the stock capital gains tax guide 2026.

Scenario 3: A Dividend-Aware Income Supplement

Because XRAY pays a dividend, it can serve as a recovery position with an income kicker rather than a pure growth holding. But watch free cash flow stability and the capital-allocation priority (dividend vs buyback vs debt paydown vs reinvestment) more than the headline yield, since a turnaround may steer cash toward deleveraging first and hold dividend growth flat.

If income is the center of your portfolio, pair XRAY as a recovery satellite alongside a proven dividend ETF rather than leaning on it alone for yield.

👉 The foundations of a dividend-led US equity strategy are set out in the SCHD dividend ETF guide 2026.

---

XRAY vs Peers: Where It Sits in a Portfolio

Comparing XRAY with names that are either similar or deliberately contrasting sharpens its position.

Company	Category	Demand character	Profile	Cycle sensitivity
XRAY (Dentsply Sirona)	Full-line dental consumables and equipment	Consumables necessary, equipment discretionary	Value/recovery (turnaround)	Medium
ALGN (Align Technology)	Clear aligners	Elective, aesthetic	Consumer-style growth	High
TMO (Thermo Fisher)	Life-science tools and consumables	Research and diagnostics essential	Quality compounder	Low to medium
ELV (Elevance Health)	Health insurance	Necessary coverage	Defensive value	Low

XRAY’s spot in this table is a middle ground: not as cyclical as Align, not as steady as Thermo Fisher. The appeal of that middle ground comes from the discount; the risk comes from execution. Want a growth bet and ALGN or TMO is cleaner. Want an undervalued-recovery bet and XRAY is the candidate.

The key is not to mistake XRAY for a “dental defensive.” Consumables are defensive, but equipment sits on top and makes the stock more volatile than a pure defensive name, and above all, execution is the variable doing the heavy lifting.

---

Metrics to Watch Each Quarter

If you own or track XRAY, prioritize a short list on results day.

First, organic consumables stability. Look past the headline total to the organic growth of consumables, stripped of FX and acquisition effects. If that floor cracks, the thesis itself is in trouble.

Second, the equipment cycle and orders. CEREC and scanner sales ride a cycle. Watch for a trough-to-recovery signal and whether practice owners’ capex appetite is reviving.

Third, operating margin recovery. The core proof of a turnaround is a cleaner cost structure. Even with flat revenue, recovering margin says execution is landing.

Fourth, free cash flow and capital allocation. Is cash generation steady, is debt coming down, and is the priority among dividend, buyback, and reinvestment consistent?

Fifth, the implant and aligner growth options. Track whether they are actually compounding or losing share, while remembering these are upside options, not the floor.

Put the five together and you can judge whether execution is genuinely improving, well beyond a headline “revenue grew X percent.”

---

Who XRAY Is Actually For

My overall verdict: Dentsply Sirona is a bet on the gap between asset quality and execution quality. The recurring consumables floor, the CEREC installed base as a hidden annuity, and the breadth of a full-line portfolio are all real. But the equipment cycle layered on top, the merger hangover, and the scale gap versus Align keep this stock parked in a “cheap but patience-required” seat.

It is not for the investor who wants clarity of growth. It is for the investor who can wait, checking quarterly metrics, while an undervalued quality asset re-rates on improving execution. Conviction here comes from the evidence of execution, not from the assets. Hold that one idea and your posture toward XRAY becomes clear.

---

Further Reading

• 👉 TMO Thermo Fisher Stock Outlook 2026: Compounding on Life-Science Consumables
• 👉 ELV Elevance Health Stock Outlook 2026: The Value in a Health-Insurance Defensive
• 👉 ITW Illinois Tool Works Stock Outlook 2026: Compounding Through Decentralization
• 👉 MET MetLife Stock Outlook 2026: Cash Flow From Insurance and Annuities
• 👉 Stock Capital Gains Tax Guide 2026: Strategy and Practical Steps

---

This article is an investment opinion written for informational purposes and is not a recommendation to buy or sell any specific security. Investing in stocks carries the risk of loss of principal, and investment decisions should be made independently based on your own financial situation and risk tolerance. The business conditions and outlook described here reflect the time of writing; always verify the latest disclosures and consult a qualified professional before investing.